Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
2017 · New England Journal of Medicine · 5,655 citations
https://doi.org/10.1056/nejmoa1707447
I
Ian W. Flinn
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
927
Papers
54.2K
Citations
94
h-index
411
i10-index
Ian W. Flinn is an academic researcher. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 94, co-authored 788 publications.
ORCID: 0000-0001-6724-290XPapers by this author
worksEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Blood · 1,419 citations
https://doi.org/10.1182/blood-2017-04-779405
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
2014 · Blood · 623 citations
https://doi.org/10.1182/blood-2013-11-531327
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
2019 · Journal of Clinical Oncology · 286 citations
https://doi.org/10.1200/jco.18.00605
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022 · Leukemia · 194 citations
https://doi.org/10.1038/s41375-021-01485-x
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
2021 · Leukemia · 172 citations
https://doi.org/10.1038/s41375-021-01328-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat